Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt

Author

Martin Wabitsch

h-index 1 View on Semantic Scholar

We have 4 of 25 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Precision Medicine in patients with rare forms of genetic obesity: Necessity for coordinated and structured care.

Advances in research enable precision medicine for rare metabolic diseases. The approval of therapies as melanocortin-4 receptor (MC4R) agonists for the treatment of hyperphagia and obesity in monogenic disorders (POMC, PCSK1, and LEPR deficiencies) and Bardet-Biedl syndrome (BBS), affecting fewer than 1 in 20,000 (BBS...

Karine Clément, I. Farooqi, Peter Kühnen et al. · 0 citations
Open access Aug 2026

P256 - ECE_2728 - Impact of setmelanotide on metabolic index scores in Phase 3 trial participants with acquired hypothalamic obesity

Acquired hypothalamic obesity (aHO) is a rare complex disease characterized by hyperphagia and reduced energy expenditure, leading to accelerated and sustained weight gain. Commonly associated with pituitary hormone deficiencies, fatigue, or sleep disturbances, aHO puts patients at high risk for metabolic complic...

H. V. van Santen, Susan A. Phillips, J. Hamilton et al. · 0 citations
Open access Aug 2026

P255 - ECE_1844 - Efficacy and safety of setmelanotide in acquired hypothalamic obesity: Results from a double-blind, multicentre, placebo-controlled, randomised phase 3 trial

Hypothalamic melanocortin-4 receptor (MC4R) signalling is crucial for regulating hunger, satiety, and energy expenditure. Tumour/treatment-induced or traumatic brain injury to the hypothalamus can lead to hyperphagia and acquired hypothalamic obesity (aHO), for which no approved treatments exist. We present resul...

Susan A. Phillips, H. V. van Santen, J. Hamilton et al. · 0 citations
Clinical trial Open access Jul 2026

Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.

Setmelanotide led to significantly greater reductions in BMI and hunger than placebo at 52 weeks among participants 4 to 66 years of age with acquired hypothalamic obesity.

J. Miller, H. V. van Santen, Susan A. Phillips et al. · 6 citations · ⚡2

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.